Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Oncoclinicas Do Brasil Servicos Medicos EBITDA Margin % Related Terms
Oncoclinicas Do Brasil Servicos Medicos EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoclinicas Do Brasil Servicos Medicos EBITDA Margin % Chart
Oncoclinicas Do Brasil Servicos Medicos Annual Data
BSP:ONCO3 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Oncoclinicas Do Brasil Servicos Medicos's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoclinicas Do Brasil Servicos Medicos EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Oncoclinicas Do Brasil Servicos Medicos's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Oncoclinicas Do Brasil Servicos Medicos's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) has a EBITDA Margin % of -19.87% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oncoclinicas Do Brasil Servicos Medicos and its competitors. According to the industry distribution chart, Oncoclinicas Do Brasil Servicos Medicos ranks #582 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 87.7%.
Is Oncoclinicas Do Brasil Servicos Medicos' EBITDA Margin % too high?
Oncoclinicas Do Brasil Servicos Medicos' current EBITDA Margin % is -19.87%. Based on the distribution chart, Oncoclinicas Do Brasil Servicos Medicos ranks #582 out of 664 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Oncoclinicas Do Brasil Servicos Medicos has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncoclinicas Do Brasil Servicos Medicos' EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Oncoclinicas Do Brasil Servicos Medicos ranks #582 out of 664 companies for EBITDA Margin %. This places Oncoclinicas Do Brasil Servicos Medicos in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oncoclinicas Do Brasil Servicos Medicos and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncoclinicas Do Brasil Servicos Medicos's current EBITDA Margin % is -19.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoclinicas Do Brasil Servicos Medicos stock overvalued right now?
Based on GuruFocus' analysis, Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) is currently considered Possible Value Trap. The stock's GF Value™ is R$3.47, compared to a current price of R$0.68 — trading 80.4% below its estimated fair value. The current EBITDA Margin % is -19.87%. Oncoclinicas Do Brasil Servicos Medicos' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3), the current EBITDA Margin % is -19.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoclinicas Do Brasil Servicos Medicos (BSP:ONCO3) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoclinicas Do Brasil Servicos Medicos stock appears to be undervalued.
The current stock price of R$0.68 is trading 80.4% below its estimated GF Value™ of R$3.47.
GuruFocus considers Oncoclinicas Do Brasil Servicos Medicos to be Possible Value Trap.
Key valuation signals for BSP:ONCO3:
EBITDA Margin %: -19.87%
GF Value™: R$3.47 vs. price of R$0.68 (80.4% below fair value)
No single metric tells the full story. See the BSP:ONCO3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoclinicas Do Brasil Servicos Medicos Business Description
Oncoclinicas Do Brasil Servicos Medicos SA is engaged in the management and administration of oncological services. It has specialists in the areas of oncology, radiotherapy, hematology, and bone marrow transplantation, complementary care. The Group operates solely in the healthcare services segment, with an emphasis on oncology.
46GF Score
Get the complete analysis for BSP:ONCO3
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:ONCO3 has been successfully added to your 
